Companies/Lantheus Holdings, Inc.

Company profile

Lantheus Holdings, Inc.

NASDAQ: LNTH · Healthcare · Drug Manufacturers - Specialty & Generic

PublicHQ Bedford, MACIK 0001521036Reports USD

#122 of 1,394 Healthcare companies by revenue42nd-percentile growth

EA Score

78B+

FH 85DQ 81GM 55SS 76

v0.1 · 65/100 weight · provisional

↑ market scale, operating margin · ↓ revenue growth (YoY), listing tenure

Methodology →

Revenue TTM

$1.5B

Rev growth YoY (TTM)

+0.6%

Net income (FY)

$233.6M

Employees

808

Market cap

$7.2B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$1.5B$1.5B2025

Net income$233.6M$233.6M2025

Operating income$310.8M$310.8M2025

Total assets$2.2B$2.2B2025

Liabilities$1.1B$1.1B2025

Equity$1.1B$1.1B2025

Revenue trend

FY2019 – FY2025 · USD

$85.8M

FY19

$347.3M

FY19

$339.4M

FY20

$425.2M

FY21

$935.1M

FY22

$1.3B

FY23

$1.5B

FY24

$1.5B

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Product33%

PYLARIFY22%

Radiopharmaceutical Oncology22%

Total Precision Diagnostics11%

DEFINITY7%

Techne Lite2%

By geography

UNITED STATES95%

Non-US5%

The read

Lantheus Holdings, Inc. booked $1.5B in FY2025 revenue, growing 0.5% year over year — about the middle of the pack among Healthcare companies we track, at a 15.2% net margin.

Peers · Healthcare

Avantor, Inc.68B Liquidia Corporation58C PTC Therapeutics, Inc.72B Praxis Precision Medicines, Inc.61C

Key facts

CEOMary Anne Heino

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersBedford, MA

ExchangeNASDAQ: LNTH

Employees808

IPO date2015-06-25

Latest filings

8-K2026-05-07 10-Q2026-05-07 8-K2026-05-01 DEF 14A2026-03-20 10-K2026-02-26 8-K2026-02-26 8-K2025-11-12 10-Q2025-11-06

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.